Research Topics
| C A ZarateSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometryAllison C Nugent
Section on Neuroimaging in Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
Neuroimage 30:485-97. 2006....- Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patientsCarlos A Zarate
Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
Am J Psychiatry 161:169-71. 2004..The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode... - Cycling into depression from a first episode of mania: a case-comparison studyC A Zarate
Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
Am J Psychiatry 158:1524-6. 2001..The characteristics of patients who cycle from mania to major depression and the frequencies of these cycles remain poorly understood... - An open-label trial of riluzole in patients with treatment-resistant major depressionCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
Am J Psychiatry 161:171-4. 2004..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression... - Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic systemCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
Ann N Y Acad Sci 1003:273-91. 2003.... - Combination treatment in bipolar disorder: a review of controlled trialsCarlos A Zarate
The Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
Bipolar Disord 5:217-25. 2003..This article reviews the available published data from controlled, blinded studies regarding combination treatments in the different treatment phases of bipolar disorder... - Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiologyJ A Quiroz
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
Mol Psychiatry 9:756-76. 2004..While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness... - Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal studyC A Zarate
Bipolar and Psychotic Disorders Research Program, McLean Hospital, Belmont, MA, USA
J Clin Psychiatry 61:33-8. 2000..To determine the use of antipsychotics during and following inpatient treatment of patients with a first-episode of mania... - Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizersT D Gould
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
Mol Psychiatry 9:734-55. 2004.... - Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeuticsH K Manji
Laboratory of Molecular Pathophysiology, NIMH, Bethesda, MD 20892-4405, USA
Mol Psychiatry 7:S1-7. 2002 
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersGerard Sanacora
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Nat Rev Drug Discov 7:426-37. 2008..We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders...- A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depressionCarlos A Zarate
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
Arch Gen Psychiatry 63:856-64. 2006..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders... - The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disordersJing Du
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Neuropsychopharmacology 32:793-802. 2007.... - Regional cerebral glucose metabolic abnormalities in bipolar II depressionLinda Mah
Section on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
Biol Psychiatry 61:765-75. 2007..This study investigated whether cerebral metabolic abnormalities previously reported in unmedicated BD subjects are evident in depressed bipolar disorder type II (BD II) subjects receiving lithium or divalproex... - Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trialsJaskaran B Singh
Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892, USA
Bipolar Disord 8:696-709. 2006..CONCLUSIONS: Treatment of psychiatric comorbidities in bipolar disorder is not based on controlled data but is largely empirically based. Controlled trials in patients with bipolar disorder and comorbidity are urgently needed... - Riluzole in psychiatry: a systematic review of the literatureCarlos A Zarate
Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
Expert Opin Drug Metab Toxicol 4:1223-34. 2008..Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent... - Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trialRoy H Perlis
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 67:1747-53. 2006..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes... - Performance on a virtual reality spatial memory navigation task in depressed patientsNeda F Gould
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Mark O Hatfield Clinical Research Center, 10 Center Dr, Bethesda, MD 20892, USA
Am J Psychiatry 164:516-9. 2007..Findings on spatial memory in depression have been inconsistent. A navigation task based on virtual reality may provide a more sensitive and consistent measure of the hippocampal-related spatial memory deficits associated with depression... - Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptorsSungho Maeng
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Biol Psychiatry 63:349-52. 2008..Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action... - Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot studyCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Bipolar Disord 9:561-70. 2007..In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania... - A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar maniaRodrigo Machado-Vieira
Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
J Clin Psychiatry 69:1237-45. 2008..This study aimed to evaluate the efficacy and tolerability of the purinergic agents allopurinol and dipyridamole combined with lithium in bipolar mania... - Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorderRodrigo Machado-Vieira
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
J Clin Psychiatry 69:946-58. 2008..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms... - Neurobiology of bipolar disorderAndrew R Newberg
National Institute of Mental Health, 10 Center Drive, MSC 1282, Building 10 CRC, Room 7 5545, Bethesda, MD 20892 1282, USA
Expert Rev Neurother 8:93-110. 2008.... - The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effectsSungho Maeng
Curr Psychiatry Rep 9:467-74. 2007.... - The role of AMPA receptor modulation in the treatment of neuropsychiatric diseasesCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health/NIH, 10 Center Drive, Bethesda, MD 20892, USA
Exp Neurol 211:7-10. 2008 - Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorderCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 59:1006-20. 2006.... - A double-blind, placebo-controlled study of memantine in the treatment of major depressionCarlos A Zarate
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
Am J Psychiatry 163:153-5. 2006..This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans... - Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorderKristine Erickson
Mood and Anxiety Disorders Program, National Institute of Mental Health, MD 20814 9692, USA
Am J Psychiatry 162:2171-3. 2005..This study investigated performance of unmedicated depressed patients on the Affective Go/No-Go Task... - Olanzapine versus divalproex in the treatment of acute maniaMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 159:1011-7. 2002..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial... - The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrenceMauricio Tohen
Lilly Research Laboratories, Brougher Building, 525 South Meridian, Indianapolis, IN 46225, USA
Am J Psychiatry 160:2099-107. 2003..Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset following first hospitalization for mania... - Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depressionHusseini K Manji
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892-4405, USA
Biol Psychiatry 53:707-42. 2003..The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders... - Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week studyMauricio Tohen
Lilly Research Laboratories, IN 46285, USA
Am J Psychiatry 160:1263-71. 2003..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex... - Olanzapine versus placebo in acute mania: treatment responses in subgroupsRoss J Baldessarini
International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
J Clin Psychopharmacol 23:370-6. 2003..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania... - Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigineJaskaran Singh
Psychopharmacology (Berl) 173:227-8. 2004 - Glycogen synthase kinase-3: a target for novel bipolar disorder treatmentsTodd D Gould
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
J Clin Psychiatry 65:10-21. 2004..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge... - A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depressionSusan L McElroy
Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 65:204-10. 2004..Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study. We describe the results of a 52-week, open-label continuation of that trial... - Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Br J Psychiatry 184:337-45. 2004..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone... - Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targetsPaul J Carlson
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892, USA
NeuroRx 3:22-41. 2006.... - An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depressionCarlos A Zarate
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 57:430-2. 2005..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression... - Pramipexole for bipolar II depression: a placebo-controlled proof of concept studyCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institute of Health, Department of Human and Health Services, Bethesda, Maryland, USA
Biol Psychiatry 56:54-60. 2004..02). One subject on pramipexole and two on placebo developed hypomanic symptoms. CONCLUSIONS: The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression... - Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapyMauricio Tohen
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 59:62-9. 2002..CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes... - Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?Jennifer L Payne
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 1283, USA
Biol Psychiatry 52:921-6. 2002.... - Overweight and obesity in bipolar disordersPo W Wang
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2117, CA 94305-5723, USA
J Psychiatr Res 40:762-4. 2006 - Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profilingRulun Zhou
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892-3711, USA
Int J Neuropsychopharmacol 9:263-6. 2006 - Increased rate of non-right-handedness in patients with bipolar disorderCecylia Nowakowska
J Clin Psychiatry 69:866-7. 2008